BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IDP-121 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IDP-121\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07864207-3343@assetmemo.bio
DTSTAMP:20261121T005838Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:IDP-121: Phase 1/2 readout est. (NCT07864207)
DESCRIPTION:IDP-121\, phase 1/2.\nStudy: Phase 1/2 Multicenter\, Open-label
 \, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant S
 mall Cell Lung Cancer (MYCrocytic)\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/idp-121#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07864207
URL:https://assetmemo.bio/drug/idp-121#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
